Nicolas BOISGERAULT

Nicolas BOISGERAULT
Chargé de Recherche (CR2) INSERM
31 ans
Centre de Recherche en Cancérologie Nantes-Angers (CRCNA)
CARRIÈRE
2015 :
2011-2014 :
2011 :
Recrutement Inserm (CR2)
Post-doctorat à la Mayo Clinic (Rochester, MN, USA)
Doctorat de l’Université de Nantes
COMMUNICATIONS
Présentations orales
15th Annual Meeting of the American Society of Gene and Cell Therapy (Philadelphie, USA, 2012)
10th International Conference of the International Mesothelioma Interest Group IMIG (Kyoto, Japon, 2010)
7ème Congrès de la Société Francophone de Thérapie Cellulaire et Génique (Giens, France, 2008)
Posters
16th Annual Meeting of the American Society of Gene and Cell Therapy (Salt Lake City, USA, 2013)
DC2010: Forum on Vaccine Science / 11th International Symposium on DCs (Lugano, Suisse, 2010)
14th International Congress of Immunology (Kobe, Japon, 2010)
Virus Cell Death Conference (Stockholm, Suède, 2009)
9th International Conference of the IMIG (Amsterdam, Pays-Bas, 2008)
Invitations
Congrès annuel de la Société Française de Thérapie Cellulaire et Génique (Marseille, France, 2016)
Vietnam National University Cancer Research Symposium (Ho Chi Minh-Ville, Viêt-Nam, 2013)
7th International HBGP Student Council Symposium (Helsinki, Finlande, 2012)
HMGB1 Symposium (Hambourg, Allemagne, 2008)
PRINCIPALES PUBLICATIONS
Achard C, Boisgerault N, Delaunay T, Roulois D, Nedellec S, Royer PJ, Pain M, Combredet C, Mesel-Lemoine M, Cellerin L, Magnan A,
Tangy F, Grégoire M, Fonteneau JF. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type
I interferon response. Oncotarget. 2015 Dec 29;6(42):44892-904.
Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau JF. Oncolytic virotherapy for human malignant
mesothelioma: recent advances. Oncolytic virotherapy. 2015 Sep 4:133-140.
Achard C, Boisgerault N, Delaunay, T, Tangy F, Grégoire, M, Fonteneau JF. Induction of immunogenic tumor cell death by attenuated
oncolytic measles virus. Journal of Clinical & Cellular Immunology. 2015 6:291.
Rajani K, Alonso-Camino V, Boisgerault N, Vile R. (2014) Viral platforms for expression of tumour antigens in cancer immunotherapy in
Tumor immunology and immunotherapy (ed. Oxford University Press). 2014, ISBN: 9780199676866.
Kottke T*, Boisgerault N*, Diaz RM, Donnelly O, Rommelfanger-Konkol D, Pulido J, Thompson J, Mukhopadhyay D, Kaspar R, Coffey M,
Pandha H, Melcher A, Harrington K, Selby P, Vile R. Detecting and targeting tumor relapse by its resistance to innate effectors at early
recurrence. Nature Medicine. 2013 Dec;19(12):1625-31.
Boisgerault N*, Kottke T*, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington
K, Melcher A, Selby P, Vile R. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.
Molecular Therapy. 2013 Aug;21(8):1507-16.
Boisgerault N, Guillerme JB, Pouliquen D, Mesel-Lemoine M, Achard C, Combredet C, Fonteneau JF, Tangy F, Grégoire M. Natural
oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. Biomed Research International.
2013, 387362.
Guillerme JB, Boisgerault N, Roulois D, Ménager J, Combredet C, Tangy F, Fonteneau JF, Grégoire M. Measles virus vaccine-infected
tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clinical Cancer Research. 2013 Mar
1;19(5):1147-58.
Boisgerault N, Tangy F, Grégoire M. New perspectives in cancer virotherapy: bringing the immune system into play. Immunotherapy.
2010 Mar 2(2):185-99.
Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Grégoire M. Measles virus induces oncolysis of mesothelioma cells and
allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Research. 2008 Jun 15;68(12):4882-92.